■头孢洛扎/他唑巴坦是一种β-内酰胺/β-内酰胺酶抑制剂组合,对多重耐药细菌菌株具有高范围的功效和广谱作用。
■本研究旨在分析头孢特洛扎/他唑巴坦对产超广谱β-内酰胺酶(ESBLs)的大肠杆菌(ESBLs-EC)和肺炎克雷伯菌(ESBLs-KP)的体外活性。
■系统评价和荟萃分析。
■在WebofScience上进行了系统的文献检索,Embase,PubMed,Scopus,和GoogleScholar电子数据库从数据库开始到2022年12月,以涵盖与我们的范围相关的所有已发表的文章。
■最后,选择符合我们纳入标准的31篇出版物进行数据提取和综合荟萃分析软件分析。头孢洛扎/他唑巴坦对ESBLs-EC和ESBLs-KP的合并易感性估计为91.3%[95%置信区间(CI):90.1-92.5%]和65.6%(95%CI:60.8-70.2%),分别。在31项研究中,ESBLs-EC(χ2=91.621;p<0.001;I2=67.256%)和ESBLs-KP(χ2=348.72;p<0.001;I2=91.4%)存在显著异质性。大多数ESBLs-EC的临床分离株的MIC50和MIC90浓度为0.5和2µg/mL[抑制50%和90%分离株的最小抑制浓度(MIC)],分别。相比之下,大多数ESBLs-KP临床分离株的MIC50和MIC90浓度为1和32µg/mL,分别。
■根据荟萃分析结果,头孢洛扎/他唑巴坦对不同临床来源的ESBLs-EC分离株比ESBLs-KP分离株具有更有希望的体外抗菌活性。因此,头孢洛扎/他唑巴坦可以作为碳青霉烯类的替代药物。需要随机临床试验来提供临床证据来支持这些观察。
UNASSIGNED: Ceftolozane/Tazobactam is a β-lactam/β-lactamase inhibitor combination with a high range of efficacy and broad-spectrum action against multidrug-resistant bacterial strains.
UNASSIGNED: The present study aimed to analyze the in vitro activity of Ceftolozane/Tazobactam against extended-spectrum β-lactamases (ESBLs)-producing Escherichia coli (ESBLs-EC) and Klebsiella pneumonia (ESBLs-KP) in the published literature to provide international data on the antimicrobial stewardship programs.
UNASSIGNED: Systematic
review and meta-analysis.
UNASSIGNED: A systematic literature search was conducted on the Web of Science, Embase, PubMed, Scopus, and Google Scholar electronic databases from the beginning of databases to December 2022 to cover all published articles relevant to our scope.
UNASSIGNED: At last, 31 publications that met our inclusion criteria were selected for data extraction and analysis by Comprehensive Meta-Analysis Software. The pooled prevalence of Ceftolozane/Tazobactam susceptibility for ESBLs-EC and ESBLs-KP was estimated at 91.3% [95% confidence interval (CI): 90.1-92.5%] and 65.6% (95% CI: 60.8-70.2%), respectively. There was significant heterogeneity among the 31 studies for ESBLs-EC (χ2 = 91.621; p < 0.001; I2 = 67.256%) and ESBLs-KP (χ2 = 348.72; p < 0.001; I2 = 91.4%). Most clinical isolates of ESBLs-EC had MIC50 and MIC90 at a concentration of 0.5 and 2 µg/mL [minimum inhibitory concentration (MIC) at which 50% and 90% of isolates were inhibited], respectively. In contrast, most clinical isolates of ESBLs-KP had MIC50 and MIC90 at a concentration of 1 and 32 µg/mL, respectively.
UNASSIGNED: Based on the meta-analysis results, Ceftolozane/Tazobactam has a more promising in vitro antibacterial activity against ESBLs-EC isolates from different clinical sources than ESBLs-KP isolates. Therefore, Ceftolozane/Tazobactam can be a useful therapeutic drug as an alternative to carbapenems. Randomized clinical trials are needed to provide clinical evidence to support these observations.